| Name | Title | Contact Details |
|---|
Community Eldercare Services, LLC is a Tupelo, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Headquartered in Omaha, Nebraska, Banyan Medical Systems, Inc. is a leading-edge medical software development and integration company dedicated to creating solutions that transform healthcare professionals` ability to access and interact with patient information. Our products and services are also designed to optimize efficiency, improve workflow, help ensure patient safety, and provide the highest levels of productivity and flexibility. As a result, we are uniquely positioned to provide healthcare professionals with the vital information they need to deliver better, more personalized healthcare to patients whether it be in the OR, clinic, or through real-time collaboration. Banyan Medical Systems healthcare services include consultation, software development and installation, training, and service support, as well as innovative custom solutions. Banyan has developed a series of integrated solutions that provide advantages not offered elsewhere, including: •Integration with all platforms, regardless of vendor •Ability to leverage current equipment and software, creating a seamless system •Scalability for easy expansion or re-design •Portability, including remote access
Pure Power Athletics, Inc. d/b/a Makkar Athletics Group is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DDN is the largest privately held provider of outsourced services to the life-science industry. We have decades of experience in every sector, and a long track record of unparalleled client satisfaction.
We are a biopharmaceutical company developing first-in-class therapies for cancer. Imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. Telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a potent and specific inhibitor of telomerase. Based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or MF, myelodysplastic syndromes, or acute myelogenous leukemia.